Schering-Plough obtained FDA clearance to market a regimen that combines Rebetol -- an antiviral drug -- with Pegintron -- a bioengineered version of an immune-system protein called interferon -- to treat hepatitis C in children ages 3 to 17. The two-drug therapy offers extended effectiveness with the aid of pegylation, a technology used in Pegintron that allows it to remain in the blood longer.

Related Summaries